Funding of drug treatment of multiple sclerosis should not be delayed

BMJ 1997; 315 doi: https://doi.org/10.1136/bmj.315.7116.1160b (Published 01 November 1997) Cite this as: BMJ 1997;315:1160
  1. D W Paty, Professor*a
  1. a Division of Neurology, University of British Columbia, Vancouver, Canada
  2. * D W Paty participated in the trial of Betaferon and is a consultant for Schering Health, which manufactures the drug.

    Editor—I disagree with Hughes that it is appropriate to delay decisions on funding a treatment for multiple sclerosis.1 I can comment on the points that Hughes made in relation to the trial of interferon beta-lb.2 3 4

    Firstly, the blinding in the trial was performed as efficiently as possible. We used two …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription